Evidence map›Paper›PMID 42016351›Full record

ArticlePhysics and imaging in radiation oncology2026

Impact of reduced robustness settings on the necessity for proton therapy treatment plan adaptation in head-and-neck cancer patients.

Brian Zapien-Campos, Dirk Wagenaar, Tim Franssen, Hans Verbeek, Stefan Both, Peter Dendooven

Abstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brian Zapien-CamposParticle Therapy Research Center (PARTREC), Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Dirk WagenaarDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Tim FranssenDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Hans VerbeekDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Stefan BothDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Peter DendoovenParticle Therapy Research Center (PARTREC), Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Robust optimization mitigates the effects of range and setup uncertainties in intensity-modulated proton therapy (IMPT) through robustness settings. However, it increases the dose to organs-at-risk (OARs). This study investigated how reducing range robustness (RR) and setup robustness (SR) settings impacts plan adaptation frequency in IMPT of head-and-neck cancer (HNC) patients. Material and methods: A cohort of twenty-six HNC patients treated with IMPT were retrospectively analyzed. Original plans used RR/SR settings of 3%/3 mm. For each patient, four plans were generated with reduced robustness settings. All plans were robustly evaluated on weekly repeat computed tomography scans (rCTs) across 28 error scenarios, applying 2.7-3.2% range and 1 mm setup uncertainty. The failure rate of the voxel-wise minimum D Results: Fixing SR at 3 mm, each 1% reduction in RR setting reduced the mean OAR dose by 0.45  Gy (RBE) and normal tissue complication probability (NTCP) by 1.1%-points at a 3.5%-points increase in adaptation triggering rate. Implementing a RR of 3%, each 1 mm reduction in SR settings reduced the OAR dose by 1.0 Gy (RBE) and NTCP by 2.2%-points at a 7.0%-points increase in adaptation triggering rate. Conclusions: Reducing robustness margins decreased OAR dose and NTCP with a manageable increase in plan adaptation; however, larger reductions would require adaptive workflows and implementation of range uncertainty mitigation strategies before safe clinical implementation.

Indexed as

Adaptive proton therapyHead-and-neck cancerIntensity modulated proton therapyRobustness settings

Identifiers

PMID42016351
PMCPMC13094435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.